Alopecia universalis successfully treated with adalimumab

JAMA Dermatology

Volumn 150, Issue 12, 2014, Pages 1341-1344

  Gorcey, Loren ^a   Spratt, Elizabeth A Gordon ^a   Leger, Marie C ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; BIMATOPROST; DIPHENCYPRONE; LEVOTHYROXINE SODIUM; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; SQUARIC ACID; TRIAMCINOLONE ACETONIDE; ULOBETASOL PROPIONATE; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALOPECIA; ALOPECIA AREATA; ALOPECIA UNIVERSALIS; ANTIBODY DETECTION; ARTICLE; ATOPIC DERMATITIS; CASE REPORT; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HYPOTHYROIDISM; MEDICAL HISTORY; NEPHROLITHIASIS; OUTCOME ASSESSMENT; RELAPSE; REMISSION; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; VIRUS MENINGITIS; ANTAGONISTS AND INHIBITORS;

ADULT; ALOPECIA; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84918529066     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.1544     Document Type: Article

References (19)

1. Pelivani N, Hassan AS, Braathen LR, Hunger RE, Yawalkar N. Alopecia areata universalis elicited during treatment with adalimumab. Dermatology. 2008;216(4):320-323
2. Alkhalifah A, Alsantali A,Wang E, McElwee KJ, Shapiro J. Alopecia areata update, part I: clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol. 2010;62(2):177-190
3. Pelivani N, Hassan AS, Braathen LR, Hunger RE, Yawalkar N. Alopecia areata universalis elicited during treatment with adalimumab. Dermatology. 2008;216(4):320-323
4. Hordinsky MK. Overview of alopecia areata. J Investig Dermatol Symp Proc. 2013;16(1):S13-S15
5. Alkhalifah A, Alsantali A,Wang E, McElwee KJ, Shapiro J. Alopecia areata update, part II: Treatment. J AmAcad Dermatol. 2010;62(2):191-202, quiz 203-204
6. Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database Syst Rev. 2008;(2):CD004413
7. Farshi S, Mansouri P, Safar F, Khiabanloo SR. Could azathioprine be considered as a therapeutic alternative in the treatment of alopecia areata? a pilot study. Int J Dermatol. 2010;49(10):1188-1193
8. Hordinsky MK. Treatment of alopecia areata: "What is new on the horizon?" Dermatol Ther. 2011; 24(3):364-368
9. Exarchou SA, Voulgari PV, Markatseli TE, Zioga A, Drosos AA. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol. 2009;38(5): 328-331
10. Pichler WJ. Adverse side-effects to biological agents. Allergy. 2006;61(8):912-920
11. Kasumagic-Halilovic E, Prohic A, Cavaljuga S. Tumor necrosis factor-Alpha in patients with alopecia areata. Indian J Dermatol. 2011;56(5):494-496
12. Strober BE, Siu K, Alexis AF, et al. Etanercept does not effectively treat moderate to severe alopecia areata: An open-label study. J AmAcad Dermatol. 2005;52(6):1082-1084
13. Lazzarini R, Capareli GC, Buense R, Lellis RF. Alopecia universalis during treatment with leflunomide and adalimumab: case report. An Bras Dermatol. 2014;89(2):320-322
14. Navarro R, Daudén E, Gallo E, Santiago Sánchez-Mateos D, García-Diez A. Alopecia areata during treatment of psoriasis with adalimumab and leflunomide: A case and review of the literature. Skin Pharmacol Physiol. 2012;25(2):107-110
15. de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-A inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007;143(2):223-231
16. Ghoreishi M, Martinka M, Dutz JP. Type 1 interferon signature in the scalp lesions of alopecia areata. Br J Dermatol. 2010;163(1):57-62
17. Kartal ED, Alpat SN, Ozgunes I, Usluer G. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol. 2007;19(9): 817-820
18. Redler S, Albert F, Brockschmidt FF, et al. Investigation of selected cytokine genes suggests that IL2RA and the TNF/LTA locus are risk factors for severe alopecia areata. Br J Dermatol. 2012;167(6): 1360-1365
19. Kooloos WM, de Jong DJ, Huizinga TW, Guchelaar HJ. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Drug Discov Today. 2007;12(3-4): 125-131.